FDG与FMISO PET引导的调强放疗剂量递增在肺癌中的应用
本研究基于21例局部晚期非小细胞肺癌患者的前瞻性II期试验数据,利用18FDG和18F-miso PET/CT勾画靶区并制定调强放疗计划,比较标准66Gy方案与三种递增至74Gy的boost策略。结果显示各策略均能满足危及器官剂量约束,其中基于治疗中18FDG残留的boost方案D95%均值最高(73.1 Gy)。作者认为可在功能影像勾画的靶区上选择性递增剂量,最相关策略需临床试验进一步研究。
要点
- 标准计划66Gy时,三种功能靶区D95%均值分别为66.5、66.1和66.1 Gy。
- 三种boost策略均将功能靶区D95%均值提升至72Gy以上,且危及器官约束均满足。
- 基于治疗中18FDG残留的boost策略D95%均值达73.1 Gy,为四种方案中最高。
核心结论
- 可在基于18FDG和18F-miso PET/CT功能影像勾画的非小细胞肺癌靶区上选择性制定递增剂量计划。
- 最相关的策略应在临床试验中进一步研究。
研究设计与样本
- 从一项前瞻性II期试验中选取21例非小细胞肺癌患者。
- 放疗开始前行18FDG和18F-miso PET/CT,放疗期间(42Gy时)行18FDG PET/CT。
- 基于标准计划66Gy(计划1)和三种boost策略制定递增至74Gy的调强放疗计划。
主要发现
- 18FDG热点、18F-miso和治疗中18FDG的平均靶体积分别为4.8 cc(±1.1)、38.9 cc(±14.5)和36.0 cc(±10.1)。
- 标准计划66Gy下,18FDG热点、18F-miso和治疗中18FDG的D95%均值分别为66.5(±0.33)、66.1(±0.32)和66.1(±0.32)Gy。
- 情景2中,18FDG热点D95%均值为72.5(±0.25)Gy,18F-miso为67.9(±0.49)Gy,治疗中18FDG为67.9(±0.52)Gy。
- 情景3中,18F-miso D95%均值为72.2(±0.27)Gy,18FDG热点为70.4(±0.74)Gy,治疗中18FDG为69.5(±0.74)Gy。
- 情景4中,治疗中18FDG D95%均值为73.1(±0.3)Gy,18FDG热点为71.9(±0.61)Gy,18F-miso为69.8(±0.61)Gy。
关键数值与推荐
- 计划1为标准计划,处方剂量66 Gy。
- 计划2为放疗前18FDG热点(SUVmax的70%)boost,总剂量74 Gy。
- 计划3为放疗前18F-miso靶区(SUVmax > 1.4)boost,总剂量74 Gy。
- 计划4为治疗中18FDG残留(SUVmax的40%)boost,总剂量74 Gy。
- 所有情景中危及器官的剂量/体积约束均匹配。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on 18FDG and 18F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy. METHOD: Twenty-one NSCLC patients, selected from a prospective phase II trial, had 18FDG- and 18F-miso PET/CT before the start of radiotherapy and 18FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment 18FDG hotspot (70% of SUVmax) (plan 2), pre-treatment 18F-miso target (SUVmax > 1.4) (plan 3) and per-treatment 18FDG residual (40% of SUVmax). (plan 4). RESULTS: The mean target volumes were 4.8 cc (± 1.1) for 18FDG hotspot, 38.9 cc (± 14.5) for 18F-miso and 36.0 cc (± 10.1) for per-treatment 18FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for 18FDG hotspot, 18F-miso and per-treatment 18FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in 18FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in 18F-miso and per-treatment 18FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to 18F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for 18FDG hotspot and per-treatment 18FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to 18FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for 18FDG hotspot and 18F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios. CONCLUSION: Escalated doses can be selectively planned in NSCLC target volumes delineated on 18FDG and 18F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials. TRIAL REGISTRATION: (RTEP5, NCT01576796 , registered 15 june 2012).
引用
- Thureau S, Dubray B, Modzelewski R, et al. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. Radiat Oncol. 2018. PMID: 30352608. doi:10.1186/s13014-018-1147-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。